1. Other data.

Study	Comparison	ADHD symptoms ‐ total	ADHD ‐ inattentiona	ADHD ‐ hyperactivitya
Bélanger 2009	Cross‐over trial of omega‐3 PUFA vs omega‐6 PUFA ‐ first phase   SD not reported and could not be calculated.	Conners Parent ‐ mean change omega‐3: −8.8 omega‐6: −5.4	Conners Parent ‐ mean change omega‐3: −9.1 omega‐6: −7.3	Conners Parent ‐ mean change omega‐3: −7.2 omega‐6: −3.1
Brue 2001	Parallel trial of omega‐3 PUFA vs dietary supplement   SD not reported and could not be calculated.	‐	Conners Parent – non‐MPH (Ritalin) omega‐3: 12.0 supplement: 13.7	Conners Parent – non‐MPH (Ritalin) omega‐3: 9.4 supplement: 13.1 P = 0.03
			Conners Teacher – non‐MPH (Ritalin) omega‐3: 19.1 supplement: 15.3	Conners Teacher – non‐MPH (Ritalin) omega‐3: 17.9 supplement: 13.4 P = 0.04
			Conners Parent – MPH (Ritalin) omega‐3: 15.6 supplement: 14.6	Conners Parent – MPH (Ritalin) omega‐3: 13.7 supplement: 13.5
			Conners Teacher – MPH (Ritalin) omega‐3: 16.3 supplement: 12.2 P = 0.04	Conners Teacher – MPH (Ritalin) omega‐3: 10.8 supplement: 12.3
Milte 2012	Parallel trial of EPA‐rich fish oil vs DHA‐rich fish oil vs placebo	‐	‐	Correlation of PUFA Conners Parent hyperactivity score vs placebo over 4 months (95% CI) EPA: 0.98 (−1.27 to 3.23) DHA: 1.12 (−1.30 to 3.53)   Correlation of PUFA Conners Parent ADHD index vs placebo over 4 months (95% CI) EPA: 1.56 (−1.96 to 5.09) DHA: 1.64 (−2.15 to 5.43)
ADHD: attention deficit hyperactivity disorder; CI: confidence intervals; EPA: eicosapentanoic acid; DHA: docosahexanoic acid; MPH: methylphenidate; PUFA: polyunsaturated fatty acids; SD: standard deviation

^aWhere there were statistical differences between groups, P values are shown.